BHCM
HRMY icon

Brevan Howard Capital Management’s Harmony Biosciences HRMY Stock Holding History

Brevan Howard Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$706K Buy
25,188
+19,433
+338% +$637K 0.01% 1104
2025
Q4 		$215K Sell
5,755
-6,575
-53% -$216K ﹤0.01% 1541
2025
Q3 		$340K Buy
+12,330
New +$425K ﹤0.01% 1507
2025
Q2 		– Sell
-28,362
Closed -$941K – 1913
2025
Q1 		$941K Sell
28,362
-14,967
-35% -$537K 0.01% 522
2024
Q4 		$1.49M Buy
+43,329
New +$1.49M 0.01% 342
2024
Q3 		– Sell
-6,847
Closed -$207K – 1270
2024
Q2 		$207K Buy
+6,847
New +$206K ﹤0.01% 882
2024
Q1 		– Sell
-6,934
Closed -$224K – 1142
2023
Q4 		$224K Buy
+6,934
New +$194K ﹤0.01% 846

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Brevan Howard Capital Management's HRMY Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Harmony Biosciences (HRMY) stake by 338% in Q1 2026, buying an estimated $637K and bringing the position to 25,188 shares worth $706K. The position accounts for 0.01% of the portfolio, ranked #1104.

Brevan Howard Capital Management first reported a position in HRMY in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.49M in Q4 2024. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Brevan Howard Capital Management held 25,188 shares of Harmony Biosciences worth $706K as of Q1 2026.
  • Brevan Howard Capital Management bought 19,433 Harmony Biosciences shares in Q1 2026, an estimated $637K.
  • Harmony Biosciences made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1104 holding.
  • Brevan Howard Capital Management first reported a position in Harmony Biosciences in Q4 2023 and has held it in 7 quarters since.
  • Brevan Howard Capital Management's Harmony Biosciences position peaked at $1.49M in Q4 2024.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.